Management of Headache in Brain Metastasis

Initial Medical Management

The National Comprehensive Cancer Network recommends dexamethasone as the first-line treatment for headaches due to brain metastasis, with initial dosing of 4-8 mg/day for moderate symptoms, increasing to 16 mg/day for severe symptoms with marked mass effect or elevated intracranial pressure 1
Dexamethasone is the preferred glucocorticoid due to its minimal mineralocorticoid activity and should be administered once or twice daily, with a typical dose of 4-8 mg/day for moderately symptomatic patients 1
Asymptomatic patients with brain metastases typically do not require prophylactic corticosteroids, though short-term preventative steroids may be reasonable when receiving potentially edema-exacerbating local therapy, according to the National Comprehensive Cancer Network 1
Corticosteroid therapy duration should be minimized to prevent long-term sequelae and generally should be tapered rather than abruptly discontinued, as recommended by the National Comprehensive Cancer Network 1

Ensure adequate dosing of dexamethasone based on symptom severity, with a recommended dose of 4-8 mg/day for moderate symptoms and up to 16 mg/day for severe symptoms, according to the National Comprehensive Cancer Network 1

For patients with significant midline brain shift, compression of the ventricular system, obstructive hydrocephalus, intratumoral hemorrhage, or massive brain edema, surgical decompression may be necessary, as recommended by the National Comprehensive Cancer Network 3
Surgical resection should be considered for accessible solitary lesions causing significant mass effect, according to the National Comprehensive Cancer Network 4

For multiple brain metastases, whole brain radiation therapy (WBRT) is typically recommended, with a goal of reducing perilesional edema and improving headache symptoms within 1-2 weeks, according to the National Comprehensive Cancer Network 4
For limited (1-4) brain metastases, stereotactic radiosurgery (SRS) with or without WBRT may provide better local control, as recommended by the National Comprehensive Cancer Network 5

Approximately 10-20% of patients with brain metastases present with seizures at diagnosis, and anti-seizure medications should not be used as primary prophylaxis among patients with brain metastases, according to the American Academy of Neurology 6
When anti-seizure medications are required, agents that do not significantly impact hepatic metabolizing enzymes (levetiracetam, lacosamide, or lamotrigine) are preferred, as recommended by the American Academy of Neurology 6

Initial management of imaging changes related to radiation effects often involves observation, and for symptomatic radiation necrosis, glucocorticoids are first-line therapy, according to the National Comprehensive Cancer Network 7
If corticosteroids prove unsuccessful or yield unacceptable side effects, consider neurosurgical resection, laser interstitial thermal therapy (LITT), or bevacizumab, as recommended by the National Comprehensive Cancer Network 7

Occurs in up to 90% of patients with brain metastases, and consider acetylcholinesterase-inhibiting medication (donepezil) for patients with memory impairment, according to the National Comprehensive Cancer Network 7
Cognitive rehabilitation involving compensatory strategies and "cognitive exercise" paradigms has shown positive results, as recommended by the National Comprehensive Cancer Network 7

Patients with melanoma brain metastases may have higher risk of intracranial hemorrhage when receiving anticoagulation, and for patients requiring anticoagulation for venous thromboembolism, carefully weigh the indication against the risk of intracranial hemorrhage, according to the American Society of Clinical Oncology 6
Corticosteroid therapy should be tapered as quickly as the clinical situation allows due to toxicity associated with long-term (>3 weeks) use, as recommended by the National Comprehensive Cancer Network 4

Patients should have close clinical follow-up to assess response to treatment, and persistent headache despite optimal medical management should prompt re-imaging to assess disease progression, according to the National Comprehensive Cancer Network 2
Serial routine imaging and correlation with clinical status are often relied upon to evaluate treatment response, as recommended by the National Comprehensive Cancer Network 1